Understanding Kyprolis® (carfilzomib) for Injection

Kyprolis® (carfilzomib) is the second FDA-approved drug in a class of drugs called proteasome inhibitors, which block the activity of enzyme complexes called proteasomes. Proteasomes carry out the breakdown of proteins in a cell, a process that is necessary for the control of many critical cellular functions.

Update 4/22/2021